14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ABEV vs BUD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Ambev S.A. (ABEV) captures the overall head-to-head institutional edge over Anheuser-Busch INBEV SA/NV (BUD) on higher Unified Composite conviction (60.3/100 BUY vs. 34.9/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples), while BUD wins 4–1 across the 6-pillar growth and valuation breakdown. ABEV trades at $2.71 (13.5x Forward P/E, 26.1% operating margin) versus BUD at $84.55 (17.4x Forward P/E, 26.7% operating margin).
Growth vs. Quality Trade-Off: ABEV earns the overall head-to-head edge with a stronger Unified Composite Score (60.3/100 BUY vs. BUD 34.9/100 SELL) and 0.54β · 58% Vol risk profile, whereas BUD leads top-line expansion (+9.1% YoY revenue growth, 1.74x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: ABEV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.2); meanwhile BUD trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABEV vs BUD. Trailing 12-month operating profitability (ABEV 26.1% vs BUD 26.7%) and valuation multiples (ABEV 13.5x vs BUD 17.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Beverages - Brewers value chain with $42.6B market capitalization and 26.1% operating margin.
OpEx & R&D Reinvestment25.7% of Rev ($4.25B)
90D Engineering Disclosures0 Published
BUD Moat ProfileScale & Operating Efficiency Moat
Beverages - Brewers Operator
Competes within the Beverages - Brewers value chain with $167.3B market capitalization and 26.7% operating margin.
OpEx & R&D Reinvestment29.8% of Rev ($19.1B)
90D Engineering Disclosures0 Published
Investor FAQ ABEV vs BUD Key Questions & Quantitative Answers
As of Nov 16, 2026, Ambev S.A. (ABEV) captures the overall head-to-head institutional edge over Anheuser-Busch INBEV SA/NV (BUD) on higher Unified Composite conviction (60.3/100 BUY vs. 34.9/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples), while BUD wins 4–1 across the 6-pillar growth and valuation breakdown. ABEV trades at $2.71 (13.5x Forward P/E, 26.1% operating margin) versus BUD at $84.55 (17.4x Forward P/E, 26.7% operating margin). Growth vs. Quality Trade-Off: ABEV earns the overall head-to-head edge with a stronger Unified Composite Score (60.3/100 BUY vs. BUD 34.9/100 SELL) and 0.54β · 58% Vol risk profile, whereas BUD leads top-line expansion (+9.1% YoY revenue growth, 1.74x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ABEV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.2); meanwhile BUD trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BUD leads the Growth & Scale pillar: ABEV posts +3.6% YoY revenue growth and -9.4% YoY earnings growth on $16.6B TTM revenue (51.8% gross margin, 26.1% operating margin), compared with BUD at +9.1% YoY revenue growth and +52.5% YoY earnings growth on $64.0B TTM revenue (56.5% gross margin, 26.7% operating margin). On trailing 12-month operating scale, ABEV generates $16.6B in USD-normalized revenue versus $64.0B for BUD. In operating R&D and SG&A reinvestment, ABEV deploys 25.7% of Rev ($4.25B) (0 90-day corporate R&D disclosures) versus 29.8% of Rev ($19.1B) (0 disclosures) for BUD.
ABEV screens cheaper on headline valuation multiples. ABEV trades at 13.5x Forward P/E, 14.6x Trailing P/E, 1.92x PEG, and 2.6x EV/Revenue (30.0% EBITDA margin), whereas BUD trades at 17.4x Forward P/E, 17.3x Trailing P/E, 1.74x PEG, and 2.6x EV/Revenue (31.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABEV (17.6% ROE) versus BUD (11.4% ROE) capital efficiency.
In options market volatility and institutional positioning, ABEV carries 13.5% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.54β · 58% Vol realized risk). By comparison, BUD carries 23.6% implied volatility (42nd %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.23β · 33% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.